N James

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
  2. doi request reprint Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
    Nicholas D James
    University of Birmingham, School of Cancer Sciences, Edgbaston, Birmingham B15 2TT, United Kingdom
    N Engl J Med 366:1477-88. 2012
  3. pmc Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 10:39. 2009
  4. ncbi request reprint The changing pattern of management for hormone-refractory, metastatic prostate cancer
    N D James
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK
    Prostate Cancer Prostatic Dis 9:221-9. 2006
  5. ncbi request reprint A study of information seeking by cancer patients and their carers
    N James
    School of Education, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Clin Oncol (R Coll Radiol) 19:356-62. 2007
  6. doi request reprint Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial
    Nicholas D James
    School of Cancer Sciences, University of Birmingham, Birmingham, UK
    Eur Urol 55:1112-23. 2009
  7. doi request reprint Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
    Nicholas D James
    Division of Cancer Studies, University of Birmingham, Birmingham, UK
    BJU Int 106:966-73. 2010
  8. doi request reprint Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors
    N James
    Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    Clin Oncol (R Coll Radiol) 21:610-6. 2009
  9. ncbi request reprint BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 10:571-6. 2003
  10. ncbi request reprint Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
    P W Cooke
    Departments of Urology and Pathology, Queen Elizabeth Hospital, and CRC Institute for Cancer Studies, University of Birmingham, Birmingham, UK
    BJU Int 85:829-35. 2000

Collaborators

Detail Information

Publications26

  1. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
    ..We describe methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned intermediate analysis and (2) adding a new research arm during the trial...
  2. doi request reprint Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
    Nicholas D James
    University of Birmingham, School of Cancer Sciences, Edgbaston, Birmingham B15 2TT, United Kingdom
    N Engl J Med 366:1477-88. 2012
    ..In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone...
  3. pmc Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 10:39. 2009
    ..The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases...
  4. ncbi request reprint The changing pattern of management for hormone-refractory, metastatic prostate cancer
    N D James
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK
    Prostate Cancer Prostatic Dis 9:221-9. 2006
    ..Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway...
  5. ncbi request reprint A study of information seeking by cancer patients and their carers
    N James
    School of Education, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Clin Oncol (R Coll Radiol) 19:356-62. 2007
    ..To examine cancer patients' and carers' use of, and attitudes to, the Internet as an information source compared with other media...
  6. doi request reprint Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial
    Nicholas D James
    School of Cancer Sciences, University of Birmingham, Birmingham, UK
    Eur Urol 55:1112-23. 2009
    ..The endothelin-A receptor (ETAR) has been implicated in the progression of prostate cancer...
  7. doi request reprint Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
    Nicholas D James
    Division of Cancer Studies, University of Birmingham, Birmingham, UK
    BJU Int 106:966-73. 2010
    ....
  8. doi request reprint Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors
    N James
    Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    Clin Oncol (R Coll Radiol) 21:610-6. 2009
    ..To determine whether primary care trusts' agreement or refusal to fund sorafenib or sunitinib affects outcomes for patients with metastatic renal cell carcinoma...
  9. ncbi request reprint BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 10:571-6. 2003
    ..This study shows that over-expression of BCL2 in patients receiving synchronous chemoradiotherapy is an independent indicator of poor survival in muscle invasive TCC of the bladder...
  10. ncbi request reprint Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
    P W Cooke
    Departments of Urology and Pathology, Queen Elizabeth Hospital, and CRC Institute for Cancer Studies, University of Birmingham, Birmingham, UK
    BJU Int 85:829-35. 2000
    ....
  11. ncbi request reprint CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule
    D H Palmer
    CR UK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TA, UK
    Oncol Rep 12:679-82. 2004
    ..These data may be relevant as a diagnostic tool; in providing insight into progression of cancer from normal epithelium; and in identifying novel therapeutic strategies for prostate cancer...
  12. doi request reprint The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines
    N D James
    Cancer Centre, University Hospital Birmingham Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    Clin Oncol (R Coll Radiol) 20:599-605. 2008
    ..To re-audit national radiotherapy practice in head and neck cancer to assess the effect of new guidelines...
  13. pmc A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham B15 2TT, UK
    Br J Cancer 91:844-9. 2004
    ..The overall median survival was 16 months (range 10.1-26.6 months). G plus C every 3 weeks is active and well tolerated in an outpatient setting, even in patients receiving prior platinum-based regimens and with poor renal reserve...
  14. pmc Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
    S A Hussain
    Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Br J Cancer 90:2106-11. 2004
    ..A national phase III trial BC2001 (www.bc2001.org.uk) exploring the effects of synchronous chemoradiotherapy with this regimen is currently recruiting...
  15. ncbi request reprint A national audit of radiotherapy in head and neck cancer
    N D James
    Cancer Research UK, Institute for Cancer Studies, Edgbaston, Birmingham, UK
    Clin Oncol (R Coll Radiol) 15:41-6. 2003
    ..To undertake a national audit of radiotherapy practice in head and neck cancer to estimate compliance with published guidelines and national standards...
  16. pmc Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
    S A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Br J Cancer 96:104-9. 2007
    ..This study showed in both univariate and multivariate analysis that survival is significantly inferior in patients with tumour expressing CA IX. Prospective studies are underway to investigate this correlation in clinical trial setting...
  17. ncbi request reprint CD40 expression in bladder cancer
    P W Cooke
    CRC Institute for Cancer Studies, University of Birmingham, Birmingham, U K
    J Pathol 188:38-43. 1999
    ..It also raises the possibility of the future development of CD40/CD40 ligand-based immunotherapy for bladder cancer...
  18. pmc Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, UK
    Br J Cancer 88:586-92. 2003
    ..Our results also raise the possibility of the future development of CD40- and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival...
  19. ncbi request reprint Is gene therapy the answer for prostate cancer?
    P Patel
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK
    Prostate Cancer Prostatic Dis 7:S14-9. 2004
    ..Although significant hurdles remain to be overcome, early clinical trial results are encouraging, suggesting that gene therapy may become an important treatment option for prostate cancer...
  20. ncbi request reprint Combining gene and immunotherapy for prostate cancer
    J G Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK
    Prostate Cancer Prostatic Dis 11:187-93. 2008
    ..The mechanism of this improved response is however likely to be non-immune based as it lacks a memory effect...
  21. ncbi request reprint The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma
    D Wilson
    The Cancer Centre, University Hospital Birmingham, Queen Elizabeth Medical Center, Edgbaston, Birmingham, UK
    Clin Oncol (R Coll Radiol) 15:400-7. 2003
    ..We aim to describe our experience with palliative radiotherapy in this context, relating Biological Effective Dose to outcome...
  22. ncbi request reprint Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer
    P W Cooke
    Queen Elizabeth Hospital, Birmingham, UK
    Eur Urol 38:279-86. 2000
    ..To establish the long-term outcome for muscle-invasive transitional cell carcinoma of the bladder treated by radiotherapy with or without neoadjuvant cisplatin...
  23. doi request reprint A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT
    G S Cruickshank
    University of Birmingham and University Hospital Birmingham, Birmingham, UK
    Appl Radiat Isot 67:S31-3. 2009
    ..In particular we note that the peak (10)B concentration in blood was 28.1 mg/ml for a total BPA administration of 350 mg/kg which is very consistent with the previous experience with BPA-fructose reported by the Helsinki group...
  24. pmc A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer
    N D James
    CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TA, UK
    Br J Cancer 85:152-6. 2001
    ..The PSA relative velocity on therapy decreased in 15/18 (83%) assessable patients compared to pre-study. GM-CSF and MDX-H210 is active in hormone refractory prostate carcinoma with acceptable toxicity; further studies are warranted...
  25. ncbi request reprint A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer
    S A Hussain
    CRC Institute for Cancer Studies. University of Birmingham, Edgbaston, United Kingdom
    Ann Oncol 12:929-35. 2001
    ..Overall 12-month survival was 65%. CONCLUSION: Chemoradiotherapy with the five-day schedule is feasible with acceptable toxicity in poor prognosis patients. A randomised trial is being launched...
  26. ncbi request reprint National survey of radiotherapy fractionation practice in 2003
    M V Williams
    Oncology Centre, Addenbrooke s NHS Trust, Cambridge, UK
    Clin Oncol (R Coll Radiol) 18:3-14. 2006
    ..To document UK practice in radiotherapy fractionation...